Intuitive Surgical (Intuitive Surgical (ISRG)) reported its second-quarter results after Thursday's closing bell, and on paper, they looked pretty good. The robotic surgery pioneer beat analyst estimates on both the top and bottom lines. But the stock still took a hit, dropping more than 8% in extended trading. Let's dig into the numbers.

Inside the Q2 Report

Intuitive Surgical reported quarterly earnings of $2.80 per share, which beat the Street estimate of $2.50 by 12%. Revenue came in at $2.89 billion, topping the analyst consensus of $2.82 billion.

Here are the key operational highlights from the quarter:

• Worldwide procedures (da Vinci and Ion combined) grew about 16% compared with the second quarter of 2025. Da Vinci procedures grew roughly 15%, while Ion procedures surged 36%.
• The company placed 468 da Vinci surgical systems, up from 395 a year ago. That included 246 of the newer da Vinci 5 systems, compared with 180 in the same quarter last year.
• The installed base of da Vinci systems reached 11,710 as of June 30, 2026, up 12% from 10,488 a year earlier.
• The Ion endoluminal system installed base grew to 1,096 systems, a 21% increase from 905 systems in the prior year.

“We are pleased with company performance this quarter, which reflects the strength of our portfolio — from da Vinci and Ion to our growing digital solutions,” said Dave Rosa, Intuitive CEO.

So why the stock drop? Sometimes the market's expectations are higher than the numbers show, or traders may be reacting to other factors. Whatever the reason, Intuitive Surgical shares were down 8.53% to $368.99 in Thursday's extended trading.